Akebia Therapeutics, Inc.2025财年第一财季实现净利润6.11百万美元，同比增加133.96%

市场透视05-18

5月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2025财年第一财季净利润为6.11百万美元，同比增加133.96%；其中营业收入为57.34百万美元，同比增加75.84%，每股基本收益为0.03美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.86亿美元，其中短期债务24.13百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536582502?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-18 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536582502","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics, Inc.2025财年第一财季实现净利润6.11百万美元，同比增加133.96%","media":"市场透视","content":"<div>\n<p>5月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2025财年第一财季净利润为6.11百万美元，同比增加133.96%；其中营业收入为57.34百万美元，同比增加75.84%，每股基本收益为0.03美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.86亿美元，其中短期债务24.13百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000115a6e2d7ec&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics, Inc.2025财年第一财季实现净利润6.11百万美元，同比增加133.96%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics, Inc.2025财年第一财季实现净利润6.11百万美元，同比增加133.96%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-18 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000115a6e2d7ec&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2025财年第一财季净利润为6.11百万美元，同比增加133.96%；其中营业收入为57.34百万美元，同比增加75.84%，每股基本收益为0.03美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.86亿美元，其中短期债务24.13百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000115a6e2d7ec&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000115a6e2d7ec&s=b","article_id":"2536582502","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000115a6e2d7ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536582502","pubTimestamp":1747497623,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月18日，Akebia Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为6.11百万美元，同比增加133.96%；其中营业收入为57.34百万美元，同比增加75.84%，每股基本收益为0.03美元。从资产负债表来看，Akebia Therapeutics, Inc.总负债2.86亿美元，其中短期债务24.13百万美元，资产负债比为1.09，流动比率为0.03。机构评级：截至2025年5月18日，当前有5家机构对Akebia Therapeutics, Inc.目标价做出预测，其中目标均价为7.30美元，其中最低目标价为6.00美元，最高目标价为10.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Akebia Therapeutics, Inc. achieved a net profit of US $6.11 million in the first quarter of fiscal year 2025, a year-on-year increase of 133.96%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"AKBA":1},"content_text":"5月18日，Akebia Therapeutics, Inc.（AKBA.US）公布财报，公告显示公司2025财年第一财季净利润为6.11百万美元，同比增加133.96%；其中营业收入为57.34百万美元，同比增加75.84%，每股基本收益为0.03美元。从资产负债表来看，Akebia Therapeutics, Inc.（AKBA.US）总负债2.86亿美元，其中短期债务24.13百万美元，资产负债比为1.09，流动比率为0.03。机构评级：截至2025年5月18日，当前有5家机构对Akebia Therapeutics, Inc.目标价做出预测，其中目标均价为7.30美元，其中最低目标价为6.00美元，最高目标价为10.00美元。公司简介：Akebia Therapeutics Inc是一家综合性生物制药公司。该公司的经营部门是开发和商业化用于肾脏疾病患者的新疗法。该公司目前的产品组合包括Auryxia(铁柠檬酸盐)，一种在美国批准并上市的药物，用于控制透析依赖性慢性肾病成人患者的血清磷水平和治疗缺铁性贫血，用于非透析依赖性慢性肾病成人患者，Vafseo (vadadustat)，一种口服缺氧诱导因子脯氨酰羟化酶抑制剂。HIF-PH抑制剂在日本被批准用于治疗成人慢性肾脏疾病引起的贫血，处于临床前开发阶段。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536582502","isCrawlerRequest":true}